231 related articles for article (PubMed ID: 26866578)
1. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
[TBL] [Abstract][Full Text] [Related]
4. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
7. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
[TBL] [Abstract][Full Text] [Related]
8. Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation.
Westwood A; Glover A; Hutchins G; Young C; Brockmoeller S; Robinson R; Worrilow L; Wallace D; Rankeillor K; Adlard J; Quirke P; West N
J Clin Pathol; 2019 Jun; 72(6):443-447. PubMed ID: 30723092
[TBL] [Abstract][Full Text] [Related]
9. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
10. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
12. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
13. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
[TBL] [Abstract][Full Text] [Related]
14. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
[TBL] [Abstract][Full Text] [Related]
15. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
[TBL] [Abstract][Full Text] [Related]
16. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
[TBL] [Abstract][Full Text] [Related]
17. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
18. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the
Morak M; Ibisler A; Keller G; Jessen E; Laner A; Gonzales-Fassrainer D; Locher M; Massdorf T; Nissen AM; Benet-Pagès A; Holinski-Feder E
J Med Genet; 2018 Apr; 55(4):240-248. PubMed ID: 29472279
[TBL] [Abstract][Full Text] [Related]
20. A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.
Walker R; Mahmood K; Joo JE; Clendenning M; Georgeson P; Como J; Joseland S; Preston SG; Antill Y; Austin R; Boussioutas A; Bowman M; Burke J; Campbell A; Daneshvar S; Edwards E; Gleeson M; Goodwin A; Harris MT; Henderson A; Higgins M; Hopper JL; Hutchinson RA; Ip E; Isbister J; Kasem K; Marfan H; Milnes D; Ng A; Nichols C; O'Connell S; Pachter N; Pope BJ; Poplawski N; Ragunathan A; Smyth C; Spigelman A; Storey K; Susman R; Taylor JA; Warwick L; Wilding M; Williams R; Win AK; Walsh MD; Macrae FA; Jenkins MA; Rosty C; Winship IM; Buchanan DD;
J Transl Med; 2023 Apr; 21(1):282. PubMed ID: 37101184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
